Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 6/20 | 0.58 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.55 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.55 |
| ▸ | CDK7 | P50613 | 3/20 | 0.53 |
| ▸ | CCNH | P51946 | 3/20 | 0.53 |
| ▸ | MNAT1 | P51948 | 3/20 | 0.53 |
| ▸ | CDK2 | P24941 | 6/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.52 |
| ▸ | CCNK | O75909 | 1/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.52 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.51 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.48 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL558518 | 1.00 | CSNK2A1 (0.58) | CSNK2A1CSNK2A2CSNK2BCDK7CCNH | |
| SCHEMBL559092 | 0.90 | HPGDS (0.51) | CSNK2A1CSNK2A2CSNK2BCDK2CCNE1 | |
| SCHEMBL2263303 | 0.90 | HPGDS (0.51) | CSNK2A1CSNK2A2CSNK2BCDK2CCNE1 | |
| SCHEMBL10207543 | 0.89 | CDK7 (0.54) | CDK7CCNHMNAT1CDK2CCNE1 | |
| SCHEMBL560324 | 0.87 | CDK7 (0.55) | CSNK2A1CDK7CCNHMNAT1CDK2 | |
| SCHEMBL558911 | 0.87 | CDK2 (0.52) | CSNK2A1CDK7CCNHMNAT1CDK2 | |
| SCHEMBL560325 | 0.87 | CDK7 (0.55) | CSNK2A1CDK7CCNHMNAT1CDK2 | |
| SCHEMBL558912 | 0.87 | CDK2 (0.52) | CSNK2A1CDK7CCNHMNAT1CDK2 | |
| SCHEMBL14676324 | 0.86 | MAPK1 (0.56) | CSNK2A1CSNK2A2CSNK2BCDK7CCNH | |
| SCHEMBL559021 | 0.86 | BRAF (0.59) | CSNK2A1CSNK2A2CSNK2BCDK7CCNH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-7998978-B2 | Substituted 2-amino-fused heterocyclic compounds | PFIZER INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998978-B2 | Substituted 2-amino-fused heterocyclic compounds | PFIZER INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998978-B2 | Substituted 2-amino-fused heterocyclic compounds | PFIZER INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| EP-2024342-A2 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | Pfizer Products Incorporated (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007125405-A2 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | CSNK2A1 81/4885CSNK2A2 96/4885CSNK2B 162/4885 |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | CSNK2A1 81/4885CSNK2A2 96/4885CSNK2B 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.